Silicon Dioxide

Summary

Silicon Dioxide (CHEMBL2108563) is a phase-3 clinical-stage unknown; indicated across 2 conditions including allergic disease and dental fluorosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108563
Name	Silicon Dioxide
Type	Unknown
Max phase	3

Also known as: Silica gel, Silicon dioxide, colloidal, SID144211605, SILICON DIOXIDE, silicon dioxide

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	3	MONDO:0005271	MONDO:0005271
dental fluorosis	1	MONDO:0006722	EFO:1000892

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00763269	PHASE3	COMPLETED	The Efficacy of a Toothpaste to Reduce Sensitivity
NCT04009889	Not specified	COMPLETED	Impact of Oral Probiotic Blend on Pregnancy Outcome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).